
Kalkine: ASX 200 Biotech Firm Mesoblast Gains Momentum Following FDA Developments
Highlights Mesoblast (ASX:MSB) reports positive discussions with the US FDA on cardiac treatment Revascor Upcoming FDA meeting scheduled for Ryoncil’s adult trial in graft versus host disease Progress across two key programs supports sentiment in the …